$GRTX News
Last published 2y ago
- 2y agoGRTXGalera Announces Board Approval of Complete Liquidation and DissolutionGlobeNewswireMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that
- 2y agoGRTXGalera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswireMALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the
- 2y agoGRTXGalera Adopts Limited Duration Stockholder Rights AgreementGlobeNewswireMALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to
- 2y agoGRTXGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireMALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to
- 2y agoGRTXGalera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireFDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE
- 3y agoGRTXGalera Announces Receipt of Type A Meeting Minutes and Strategic UpdateGlobeNewswireFDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives
- 3y agoGRTXGalera Schedules Type A Meeting with FDA to Discuss Next Steps for AvasopasemGlobeNewswireMALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireMALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireCompany received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with reduction in
- 3y agoGRTXGalera Receives Complete Response Letter from U.S. FDA for Avasopasem ManganeseGlobeNewswireThe Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and
- 3y agoGRTXGalera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual MeetingGlobeNewswireAs previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of kidney function at month 3
- 3y agoGRTXGalera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic CancerGlobeNewswireMALVERN, Pa., May 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics
- 3y agoGRTXGalera Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesGlobeNewswireAvasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering Company
- 3y agoGRTXGalera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics
- 3y agoGRTXGalera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireMALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck OncologyGlobeNewswireMALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireAvasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct offering
- 3y agoGRTXGalera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and WarrantsGlobeNewswireMALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral MucositisGlobeNewswirePDUFA target date of August 9, 2023 Avasopasem would be first drug approved for SOM in patients with head and neck cancer MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX),
- 3y agoGRTXGalera Submits New Drug Application for Avasopasem for Severe Oral MucositisGlobeNewswireMALVERN, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 3y agoGRTXGalera to Present at Piper Sandler Annual Healthcare ConferenceGlobeNewswireMALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 4y agoGRTXGalera Reports Third Quarter 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireCompany on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall
- 4y agoGRTXGalera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual MeetingGlobeNewswireTumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year Meta-analysis of ROMAN and
- 4y agoGRTXGalera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual MeetingGlobeNewswireMALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to tran
- 4y agoGRTXGalera to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireMALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to tran
- 4y agoGRTXGalera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical OfficerGlobeNewswireMALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to tran
- 4y agoGRTXGalera Reports Second Quarter 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireCompany on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 stage of GRECO-1 trial demonstrate
- 4y agoGRTXGalera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLCGlobeNewswireRucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of this trial MALVERN, Pa., June
- 4y agoGRTXGalera to Present at Jefferies Healthcare ConferenceGlobeNewswireMALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to trans
- 4y agoGRTXGalera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of AvasopasemGlobeNewswireAvasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on track to submit NDA to U.S. FDA for avasopasem by en
- 4y agoGRTXGalera Reports First Quarter 2022 Financial Results and Recent Corporate UpdatesGlobeNewswireCompany plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation
- 4y agoGRTXGalera Announces Plan to Submit Avasopasem NDA by Year EndGlobeNewswireMALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transf
- 4y agoGRTXGalera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced EsophagitisGlobeNewswireIncidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutic
- 4y agoGRTXGalera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireMALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to tran
- 4y agoGRTXGalera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate UpdatesGlobeNewswirePositive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in esophagitis and GRECO-1 in lung cancer expected in 1H 20
- 4y agoGRTXGalera to Present at H.C. Wainwright BioConnect ConferenceGlobeNewswireMALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to trans
- 4y agoBRTXCANFDBVTFRO+1Thinking about buying stock in BioRestorative Therapies, DBV Technologies, Frontline, Galera Therapeutics, or Can Fite Biopharma?PR NewswireNEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRTX, DBVT, FRO, GRTX, and CANF.
- 4y agoGRTXMNSOPRLDPRPL+1Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?PR NewswireNEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL.
- 4y agoGILDGRTXITCILCTX+2The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026PR NewswirePALM BEACH, Fla., Dec. 21, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, l
- 4y agoGRTXNIOOGENOXY+1Thinking about buying stock in Galera Therapeutics, Nio, Oragenics, Spruce Biosciences, or Occidental Petroleum?PR NewswireNEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, NIO, OGEN, SPRB, and OXY. T
- 4y agoBCTXGRTXKXINPBTS+1Thinking about buying stock in Kaixin Auto, Stryve Foods, Powerbridge Technologies, Briacell Therapeutics, or Galera Therapeutics?PR NewswireNEW YORK, Dec. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KXIN, SNAX, PBTS, BCTX, and GRTX.
- 4y agoALZNCTICGRTXONCY+1Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia TherapeuticsPR NewswirePALM BEACH, Fla., Dec. 15, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming ce
- 4y agoAVCTBFRIGRTXMESO+1Thinking about buying stock in Galera Therapeutics, Mesoblast, SeaChange International, American Virtual Cloud Technologies, or Biofrontera?PR NewswireNEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, MESO, SEAC, AVCT, and BFRI.
- 4y agoAGLEALZNGRTXSELB+1Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences?PR NewswireNEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB.
- 4y agoGRTXGalera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of AvasopasemGlobeNewswireCorrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europ
- 4y agoGRTXGalera to Present at Two Upcoming Investor Conferences in NovemberGlobeNewswireMALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to trans
- 5y agoGRTXGalera Reports Third Quarter 2021 Financial Results and Recent Corporate UpdatesGlobeNewswireRecently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in combination with SBRT in patients with NSCLC and pancrea
- 5y agoFCELGRTXMROSOFI+1Thinking about buying stock in FuelCell Energy, Waitr Holdings, Galera Therapeutics, Marathon Oil, or SoFi Technologies?PR NewswireNEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FCEL, WTRH, GRTX, MRO, and SOFI. T
- 5y agoGRTXGalera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral MucositisGlobeNewswirePrimary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median durationAvasopasem was generally well tolerated compared to placeb
- 5y agoGRTXGalera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance OfficerGlobeNewswireMALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to trans